Conference abstract · 13 Sep 2016
Conference abstractPublished 24 Aug 2016
New macrolides: A much needed evolution
Cempra Pharmaceuticals, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The macrolide class of antibiotics has been in clinical use for over 50 years being the backbone of many empirical therapies in both adults and children. The first of the class was erythromycin which was acid labile and of modest antibacterial activity thus clarithromycin was chemically modified from the parent molecule to yield a more acid stable drug with better activity. Additionally it could be given twice a day. Soon after this improvement azithromycin was developed as a once a day drug with an almost similar bacterial profile. However as these antibiotics was used extensively often as initial therapy in a broad range of respiratory infections across the globe resistance developed by two different mechanisms and thereby reducing activity against Streptococcus pneumoniae quite significantly. Indeed in some parts of Asia resistance rates of 80-90% are reported although in the USA it is currently around half of all strains are resistant to the most frequently prescribed oral drug for community acquired pneumonia. In view of this the first ketolide telithromycin was developed to be active against the resistant pneumococcal isolates. It was used very broadly in respiratory tract infections and was soon noticed to cause several severe adverse reactions including liver failure, visual disturbances, neurological events and other significant reactions. In the intervening decade solithromycin, a fourth generation macrolide and the first fluoroketolide has been developed initially for community acquired bacterial pneumonia based on its superior antibacterial activity especially against azithromycin resistant pneumococci based on a unique mode of action. The clinical dossier is with the FDA for review by end of 2016.
Subjects
BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Brief report · 26 Dec 2022
How Much Morphological Support is Needed to Change a Phylogenomic Based Recalcitrant Node?
Editorial · 20 Oct 2016
The Fight against Bacterial Resistance - New Initiatives but Much Still Needed
Mini review · 2018
[No] Need for Speed: Late-onset Diseases as Evolution's Power Brakes
Conference abstract · 19 Oct 2016
Evolution of Structure-Function paradigm in Biopharmaceutics based on Global Regulatory Needs
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectBiology
- BylineArticles whose byline prints “Glenn S Tillotson”
